Northland Capmk Has Positive Outlook of BLFS Q1 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Analysts at Northland Capmk raised their Q1 2025 earnings per share (EPS) estimates for shares of BioLife Solutions in a report released on Monday, March 3rd. Northland Capmk analyst C. Byrnes now anticipates that the medical equipment provider will post earnings per share of ($0.02) for the quarter, up from their previous forecast of ($0.03). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.03) EPS.

Other equities analysts have also recently issued reports about the company. TD Cowen raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. KeyCorp raised their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright raised their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday. Benchmark reissued a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $26.80 on Thursday. The business’s 50-day moving average price is $26.67 and its two-hundred day moving average price is $25.49. BioLife Solutions has a twelve month low of $14.84 and a twelve month high of $29.55. The stock has a market cap of $1.24 billion, a P/E ratio of -25.28 and a beta of 1.91. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same quarter last year, the firm posted ($0.21) EPS.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently made changes to their positions in BLFS. Harbor Capital Advisors Inc. grew its position in shares of BioLife Solutions by 31.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 52,449 shares of the medical equipment provider’s stock worth $1,313,000 after buying an additional 12,421 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of BioLife Solutions by 4.7% in the 3rd quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after buying an additional 8,580 shares during the last quarter. Summit Global Investments bought a new stake in shares of BioLife Solutions in the 3rd quarter worth approximately $228,000. Curi RMB Capital LLC grew its position in shares of BioLife Solutions by 0.5% in the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock worth $10,565,000 after buying an additional 2,283 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter worth approximately $57,000. 93.24% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the sale, the executive vice president now directly owns 276,315 shares in the company, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Troy Wichterman sold 987 shares of BioLife Solutions stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,978 shares of company stock worth $322,724 in the last ninety days. 2.20% of the stock is owned by insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.